SEC Company Response from TRINITY BIOTECH PLC (TRIB) (CIK 0000888721) (TRIB) — Mar 5, 2010
TRINITY BIOTECH PLC (TRIB) (CIK 0000888721)
Date: March 5, 2010 · CIK: 0000888721 · Accession: 0000950123-10-021187
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-22320
Referenced dates: February 24, 2010
Letter
United States Securities and Exchange Commission Trinity Biotech Plc Form 20-F for the fiscal year ended December 31, 2008 Filed April 7, 2009 File No. 000-22320
Re:
Dear Jeffrey,
In reference to your letter dated February 24, 2010, I confirm that we have now filed the following agreements as exhibits:
1.
Acquisition agreement with Cortex Biochem Inc
2.
Acquisition agreement with Sterilab Services UK
We intend to list these two agreements along with the other agreements mentioned in my letter of February 16, 2010 in the exhibit index in our next Form 20-F.
We acknowledge that:
•
it is the company’s responsibility for the adequacy and accuracy of the disclosure in its filings;
•
Commission staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
•
The company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
In the event that you have any queries please contact me at +353 1 2769800.
Yours sincerely,
/s/Kevin Tansley
Kevin Tansley
Chief Financial Officer
Trinity Biotech plc.
Show Raw Text
CORRESP
1
filename1.htm
Correspondence
March 5, 2010
Jeffrey P. Riedler
Assistant Director
United States Securities and Exchange Commission
100 First Street N.E.
Washington D.C. 20549
Re:
Trinity Biotech Plc
Form 20-F for the fiscal year ended December 31, 2008
Filed April 7, 2009
File No. 000-22320
Dear Jeffrey,
In reference to your letter dated February 24, 2010, I confirm that we have now filed the following agreements as
exhibits:
1.
Acquisition agreement with Cortex Biochem Inc
2.
Acquisition agreement with Sterilab Services UK
We intend to list these two agreements along with the other agreements mentioned in my letter of February 16, 2010 in
the exhibit index in our next Form 20-F.
We acknowledge that:
•
it is the company’s responsibility for the adequacy and accuracy of the disclosure in its filings;
•
Commission staff comments or changes to disclosure in response to staff comments do not foreclose the
Commission from taking any action with respect to the filing; and
•
The company may not assert staff comments as a defense in any proceeding initiated by the Commission or
any person under the federal securities laws of the United States.
In the event that you have any queries please contact me at +353 1 2769800.
Yours sincerely,
/s/Kevin Tansley
Kevin Tansley
Chief Financial Officer
Trinity Biotech plc.